At the time of writing, Trevi Therapeutics Inc [TRVI] stock is trading at $9.88, up 3.35%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TRVI shares have gain 12.66% over the last week, with a monthly amount glided 36.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on August 21, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $18. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on July 01, 2025, and set its price target to $25. On May 28, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $21 on the stock. Raymond James upgraded its rating to a Strong Buy and increased its price target to $29 on March 10, 2025. Needham reiterated its recommendation of a Buy and raised its price target to $25 on March 10, 2025. H.C. Wainwright reiterated a Buy rating for this stock on December 12, 2024, and upped its price target to $7.50.
For the past year, the stock price of Trevi Therapeutics Inc fluctuated between $2.36 and $9.92. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $9.88 at the most recent close of the market. An investor can expect a potential drop of -19.03% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at -0.26% with Operating Profit Margin at -352.89%, Pretax Profit Margin comes in at -324.28%, and Net Profit Margin reading is -323.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.41 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.59 points at the first support level, and at 9.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.08, and for the 2nd resistance point, it is at 10.28.
Ratios To Look Out For
It is important to note that Trevi Therapeutics Inc [NASDAQ:TRVI] has a current ratio of 22.42. Also, the Quick Ratio is 22.42, while the Cash Ratio stands at 12.67.
Transactions by insiders
Recent insider trading involved Delfini Lisa, Officer, that happened on Oct 03 ’25 when 40000.0 shares were purchased. Officer, Delfini Lisa completed a deal on Aug 27 ’25 to buy 0.31 million shares. Meanwhile, Chief Scientific Officer SCIASCIA THOMAS sold 2631.0 shares on Mar 25 ’25.
